Disease · EFO_0001425
ischemic cardiomyopathy
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. ischemic cardiomyopathy. Diseases, record EFO_0001425. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0001425
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- ischemic cardiomyopathy
- Open Targets ID
- EFO_0001425
- Highest stage of its drugs
- Phase 2, for 1 of its 15 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs15
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| OMECAMTIV MECARBIL | CHEMBL1800955 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AMIODARONE | CHEMBL633 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BEPOTASTINE BESYLATE | CHEMBL1201759 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| BISOPROLOL | CHEMBL645 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| CARVEDILOL | CHEMBL723 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| CLOPIDOGREL | CHEMBL1771 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LIPOIC ACID, ALPHA | CHEMBL33864 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LIRAGLUTIDE | CHEMBL4084119 | Protein | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LOSARTAN | CHEMBL191 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
1 to 10 of 15
See all 15 drugsTargets23
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRB1 | Adrenergic receptor beta | 5 | Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonist | Unknown | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Adrenergic receptor beta | 3 | Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor antagonist | Unknown | https://conductscience.org/library/genes/154 | Drugs and targets |
| KCNH2 | Voltage-gated inwardly rectifying potassium channel KCNH2 | 2 | HERG blocker | Unknown | https://conductscience.org/library/genes/3757 | Drugs and targets |
| ADRA1A | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRB3 | Adrenergic receptor beta | 1 | Adrenergic receptor beta antagonist | Unknown | https://conductscience.org/library/genes/155 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 1 | Type-1 angiotensin II receptor antagonist | Unknown | https://conductscience.org/library/genes/185 | Drugs and targets |
| GLP1R | Glucagon-like peptide 1 receptor | 1 | Glucagon-like peptide 1 receptor agonist | Unknown | https://conductscience.org/library/genes/2740 | Drugs and targets |
| HRH1 | Histamine H1 receptor | 1 | Histamine H1 receptor antagonist | Unknown | https://conductscience.org/library/genes/3269 | Drugs and targets |
1 to 10 of 23
See all 23 targetsTrials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00682565 | PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina | Phase 2 | 94 | 2010-02-25 | Heart Failure, Myocardial Ischemia, Angina Pectoris | OMECAMTIV MECARBIL | Its record names the disease | ClinicalTrials.gov |
| NCT01705509 | The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC) | Not applicable | 14 | 2020-02-18 | Cardiomyopathy | RANOLAZINE | Its record names the disease | ClinicalTrials.gov |
| NCT02930265 | Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy | Not applicable | 400 | Ischemic Cardiomyopathy | LIRAGLUTIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00224809 | Impact of Medical and Surgical Therapy on Functional Mitral Regurgitation | Not applicable | 250 | Cardiovascular Diseases, Heart Diseases, Coronary Disease | ASPIRIN, CLOPIDOGREL, SPIRONOLACTONE | Its record names the disease | ClinicalTrials.gov | |
| NCT03734562 | Trial to Evaluate the Efficacy and Safety of Substrate Ablation of Monomorphic Ventricular Tachycardia | Not applicable | 180 | Monomorphic Ventricular Tachycardia | AMIODARONE, SOTALOL | Its record names the disease | ClinicalTrials.gov | |
| NCT06056687 | Alpha-lipoic Acid in Diabetic Patients With Ischemic Cardiomyopathy | Not applicable | 60 | Ischemic Cardiomyopathy, Diabetes Mellitus | LIPOIC ACID, ALPHA | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials3
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0001425
GET https://conductscience.org/api/diseases/v1/EFO_0001425/targets?page=2